Eiger BioPharmaceuticals, Inc.
EIGRQ · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 17% | 11.1% | – | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 95.1% | 80.1% | 87.3% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -435.8% | -681.5% | -242.9% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -475.3% | -717.7% | -279.3% | – |
| EPS Diluted | -50.78 | -69.74 | -29.98 | -69.34 |
| % Growth | 27.2% | -132.6% | 56.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |